These are the stocks posting the largest moves before the bell.Market Insiderread more
U.S. stock futures pointed to a higher open on Monday as Treasury yields rebounded to quell fears of a possible recession.US Marketsread more
The Business Roundtable, a group of CEOs of nearly 200 major U.S. corporations, gave a new definition of the "purpose of a corporation."Marketsread more
Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
U.S. Commerce Secretary Wilbur Ross said the U.S. will extend a reprieve given to Huawei that permits the Chinese firm to buy supplies from U.S. companies.Politicsread more
Dow to jump; Trump defends economy; Huawei hopes for US reprieve; Trump and Apple's Tim Cook meet; president ties Hong Kong protests to China trade disputeMarketsread more
The U.K. prime minister prepares to meet his German and French counterparts this week.Europe Politicsread more
Amazon is raising seller fees for thousands of small and medium-sized businesses in France because of a new digital tax passed by the French government.Technologyread more
Ahead of the deadline, U.S. President Donald Trump told reporters that Huawei was a national security threat.Technologyread more
Target is launching its biggest brand yet, Good & Gather. Target expects the grocery label will be a multibillion-dollar brand by the end of 2020.Retailread more
Swiss drugmaker Roche lifted its full-year sales outlook after revenue in the first half rose 18 percent, helped by newer drugs including multiple sclerosis medicine Ocrevus and cancer immunotherapy Tecentriq.
Speaking to CNBC's Julianna Tatelbaum, the company's CEO Severin Schwan said he was "very pleased with the result for the first six months." He added that these results were "highly driven by the demand for our new medicines."
Roche now expects 2019 sales to rise at the mid- to high-single digit percentage rate, at constant exchange rates, from the previous target of mid-single digit sales growth. Profit in the first half rose 18 percent to 8.8 billion Swiss francs ($8.93 billion), while sales rose 8 percent to 30.5 billion francs, the company said in a statement.
Roche added that its delayed $4.3 billion takeover of gene therapy maker Spark Therapeutics is currently expected to be completed in 2019, and that it is working with U.S. and British regulators who are scrutinizing the deal.
"We are very confident we can answer all the questions which we will get from the authorities and then we will close the transaction by the end of the year," Schwan said.
At the same time, Roche is set to keep looking for further acquisitions.
"We will always continue to look for smaller and mid sized acquisitions, bolt on acquisitions, product or technologies which build out our franchise," Schwan told CNBC.